Second primary cancers in patients with cutaneous melanoma in anamnesis
Abstract
We have carried out the analysis of structure of recurrent malignant neoplasm by the constantly observed group of population after the radically cured MS. Materials and methods. From the year 1978 till 2011 100.000 people were under the constant clinical observation. The MS was diagnosed by 507 patients (243 men and 264 women). By all patients the diagnose was verified cytologically and/or histologically. The radical surgical cure of MS was done to 304 (60%) patients on the I stage; 106 (21%) on the II and 40 (8%) -on the III stage. By 56 (11%) people the stage was not established. In addition to the surgical cure 132 (26%) patients got chemotherapy and 7 (1,4%) immunotherapy. Later on all these patients were under the constant clinical observation. Results. Among 507 patients, who were treated for the MS, by 70 (14%) were other tumors subsequently exposed. This group includes 38(53%) men and 32(47%) women. By 70 patients were exposed 94 tumors, that chronologically appeared synchronically 81(86%) or metachronically 13 (14%). By 60 (86%) patients one tumor was diagnosed, by 6 (8%) two, by 3(4%) three, by one (1%) eleven tumors. The most often in a capacity of the second neoplasm was found basal cell carcinoma (BCC) 31 (33%) tumors. Most frequently BCC was diagnosed by men at the age of 50-59 years 14 (15%) tumors. Among the somatic oncopathology by the patients with MS in anamnesis the most often was found malignant neoplasm of the digestive tract 13 (14%) tumors, 5 (5%) of them falling to the share of stomach cancer. More seldom was diagnosed the neoplasm of prostate gland 12 (13%) neoplasias, breast cancer 8 (8,5%). Most often somatic neoplasm was exposed by men at the age of 70-79 years. By 37 (52%) patients the tumors were diagnosed after 6 or more years after the cured MS. Conclusions. After the radical treating of MS the long, maybe lifelong observations of such patients with oncologist and dermatologist are needed. A particular attention, obviously, should be given to the dermatologists’s examination of men at the age of 50-59 years and the inspection of digestive tract and prostate of men at the age of 70-79 years and the inspection of breast cancer of women at the age 70-79 years.
About the Authors
M. I. Kurdina
Central Clinical Hospital of Administration of the President of the Russian Federation; Lomonosov MSU
Russian Federation
Russian Federation
M. A. Koroleva
Central Clinical Hospital of Administration of the President of the Russian Federation; Lomonosov MSU
Russian Federation
Russian Federation
References
1. Donatus U., Gery P. Guy The health burden and economic costs of cutaneous melanoma mortality by race/ ethnicity. United States, 2000 to 2006. JAAD. 2011, v. 65, No. 1, p. 133141.
2. Koh K. Howard, Geller C. Alan. The public health future of melanoma control. JAAD. 2011, v. 65, No. 1, p. 3-5.
3. Meg Watson, Cristopher J. Johnson Melanoma surveillance in the United States: Overview of methods. JAAD. 2011, v. 65, No. 1, p. 6-16.
4. Энциклопедия клинической онкологии. Под ред. М.И. Давыдова. М., РЛС, 2005, 350 с.
5. Lens M.B., Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol. 2004, v. 150, No. 15, p. 179-185.
6. Retsas S., Mohith A., Bell J., Alexander H. Melanoma and additional primary cancers. Melanoma Res. 2000, v. 10, p. 145-152.
7. Wassberg C., Thorn M., Yuen J., Ringborg U., Hakulien T Second primary cancers in patients with cutaneous melanoma: a population-based study in Sweden. Br. J. Cancer. 1996, v. 73, p. 225-259.
8. Wu Y., Kim G.H., Wagner J.D., Hood A.F., Chuang T.Y. The association between malignant melanoma and noncutaneous malignancies. Int. J. Dermatol. 2006, v. 45, p. 529-534.
9. Crocetti E., Carli P. Risk of secondary primary cancers, others than melanoma, in an Italian population-based cohort of cutaneous malignant melanoma patients. Eur. J. Cancer Prev. 2004, v. 13, p. 33-37.
10. Schmidt-Wendtner M.N., Baumert J., Wendtner C.M., Plewig G., Volkenandt M. Risk of secondary primary malignancies in patients with cutaneous melanoma. Br. J. Dermatol. 2001, v. 145, p. 981-985.
11. Мерабишвили В.М., Чепик О.Ф. Анализ выживаемости и погодичной летальности больных злокачественной меланомой кожи на популяционном уровне. Вопр. онкол. 2006, т. 5, № 5, с. 385-391.
12. Аксель Е.М., Горбачева И.А. Заболеваемость злокачественными опухолями и смертность от них в Москве и Санкт-Петербурге в 2008 г. Вестн. РОНЦ им. Н.Н. Блохина РАМН. 2010, т. 18, № 2, с. 118-135.
13. Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2008 г. Вестн. РОНЦ им. Н.Н. Блохина РАМН. 2010, т. 18, № 2, с. 52-89.
14. Давыдов М.И., Аксель Е.М. Смертность населения России и стран СНГ от злокачественных новообразований в 2008 г. Вестн. РОНЦ им. Н.Н. Блохина РАМН. 2010, т. 18, № 2, с. 87-117.
15. Курдина М.И. Оценка эффективности диспансеризации как метода активного выявления меланомы кожи. Клин. мед. 1992, № 11, с. 68-70.
16. Gutman M., Cnaan A., Inbar M., Shafir R., Chaitchic S., Rozin R.R., Klausner J.M. Are malignant melanoma patients at higher risk for a second cancer? Cancer. 1991, v. 1, p. 660-665.
17. Wolff J., Wollina U. Second malignancies in melanoma patients in Turingia. J. Eur. Acad. Dermatol. Venerol. 2000, v. 14, p. 479-483.
Review
For citations:
Kurdina M.I., Koroleva M.A. Second primary cancers in patients with cutaneous melanoma in anamnesis. Bone and soft tissue sarcomas, tumors of the skin. 2012;(2):42-47. (In Russ.)
Views:
96
Email this article 
